Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Acrux Limited

Market Cap 9.24M 6.46M 5.61M 5.17M 4.84M 9.05M 619M 61.67M 23.87M 298M 24.26M 23.74M 1.04B P/E Ratio 2024
-3.44x
P/E Ratio 2025 -0.95x
Enterprise Value 12.01M 8.4M 7.29M 6.72M 6.3M 11.77M 804M 80.17M 31.04M 388M 31.54M 30.86M 1.35B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day-5.56%
1 week+41.67%
Current month+41.67%
1 month+41.67%
3 months+30.77%
6 months+6.25%
Current year+13.33%
1 week 0.01
Extreme 0.012
0.02
1 month 0.01
Extreme 0.009
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.16
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 2025-05-31
Director of Finance/CFO - 2021-06-20
Chief Tech/Sci/R&D Officer - 2015-02-14
Director TitleAgeSince
Director/Board Member 70 2016-05-31
Chairman 74 2005-12-31
Director/Board Member - 2013-09-30
Change 5-day change 1-year change 3-year change Capi.($)
-5.56%+41.67%-22.73%-67.92% 6.46M
+0.76%+1.44%+7.14%+83.45% 44.96B
-0.20%-3.59%+38.01%+87.26% 33.53B
+0.79%-0.46%-7.19%+45.30% 11.67B
-0.10%+1.42%+12.84%+116.57% 11.62B
+1.36%+0.78%+37.07%+126.43% 8.97B
+2.40%-0.08%+17.57%+42.98% 6.89B
-1.12%-0.56%+40.12%-18.60% 6.55B
+0.78%-0.27%+31.76%+238.31% 6.32B
-0.45%-2.96%-39.97%-6.82% 5.12B
Average -0.19%+4.21%+11.46%+64.70% 13.56B
Weighted average by Cap. +0.41%-1.10%+17.49%+83.60%

Financials

2024 2025
Net sales 5.09M 3.56M 3.09M 2.85M 2.67M 4.99M 341M 33.98M 13.16M 164M 13.37M 13.08M 571M 1.19M 832K 722K 666K 624K 1.17M 79.7M 7.94M 3.08M 38.42M 3.12M 3.06M 134M
Net income -5.8M -4.06M -3.52M -3.25M -3.04M -5.68M -388M -38.71M -14.99M -187M -15.23M -14.9M -651M -5.94M -4.16M -3.61M -3.33M -3.12M -5.82M -398M -39.68M -15.36M -192M -15.61M -15.27M -667M
Net Debt 759K 531K 461K 425K 398K 744K 50.84M 5.07M 1.96M 24.5M 1.99M 1.95M 85.2M 2.77M 1.94M 1.68M 1.55M 1.45M 2.72M 186M 18.5M 7.16M 89.49M 7.28M 7.12M 311M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
26-06-12 0.0170 $ -5.56% 2,127,316
26-06-11 0.0180 $ +12.50% 3,458,763
26-06-10 0.0160 $ +33.33% 5,602,843
26-06-09 0.0120 $ 0.00% 719,941
26-06-05 0.0120 $ 0.00% 708,933

Annual profits - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!